Ipsen Licenses Prostate Cancer Drug | April 25, 2011 Issue - Vol. 89 Issue 17 | Chemical & Engineering News
Volume 89 Issue 17 | p. 21 | Concentrates
Issue Date: April 25, 2011

Ipsen Licenses Prostate Cancer Drug

Department: Business
Keywords: tasquinimod, prostate cancer, drug development

Paris-based Ipsen will pay $35 million up front for the right to codevelop Active Biotech’s prostate cancer compound tasquinimod outside of the Americas and Japan. Active Biotech could score up to $285 million in milestone payments as the drug candidate progresses toward the market. Tasquinimod is in a Phase III trial involving men with metastatic castrate-resistant prostate cancer. Ipsen says the compound will complement its oncology portfolio.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment